IVIG vs SCIG in CIDP

Recruiting now · Phase 1

Conditions studied: CIDP, Immunoglobulin Deficiency, Chronic Inflammatory Demyelinating Polyneuropathy

In brief

Current dosing practices for immunoglobulin G (IgG) may be inadequate in extreme body weight. The current study will evaluate the influence of body composition on intravenous and subcutaneous administration of immunoglobulin G in patients.

Key facts

Study ID

NCT05584631

Run by

Rutgers, The State University of New Jersey

People needed

20

Starts

2022-09-11

Expected to finish

2026-12-01

Last updated by the study team

2025-12-11

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients aged >18 years with a current diagnosis of CIDP (based on European Federation of Neurological sciences / Peripheral Nerve Society CIDP diagnostic criteria).
• 1:1 conversion of IVIG to SCIG (weekly dose conversion) must fall within 0.2-to-0.4 mg/kg dose for SCIG.

You may not qualify if…

• Patients receiving IVIG for indications other than CIDP will be excluded.
• Patients with liver impairment (elevations in liver enzymes of greater than 3 times the upper limit of normal) or reduced renal function (CrCl < 50 mL/min) will be excluded
• Active malignancies
• Diabetes
• Myasthenia gravis
• Immunodeficiency
• Autoimmune disease

Where it is running

• Rutgers, The State University of New Jersey Clinical Research Center — New Brunswick, New Jersey, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.